name,smiles,label100,phase,moa,drug_category
ledipasvir,COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1ncc([nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C,0,Launched,HCV inhibitor,noncancer
chlorthalidone,NS(=O)(=O)c1cc(ccc1Cl)C1(O)NC(=O)c2ccccc12,0,Launched,carbonic anhydrase inhibitor,noncancer
flavoxate,Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
fluorometholone,C[C@H]1CC2C3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)C2(C)C=CC(=O)C=C12,1,Launched,glucocorticoid receptor agonist,noncancer
JNJ-38877605,Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1,0,Phase 1,tyrosine kinase inhibitor,targeted cancer
bromperidol,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1,0,Launched,dopamine receptor antagonist,noncancer
dazmegrel,Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O,0,Phase 2,thromboxane synthase inhibitor,noncancer
AT7867,Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1,1,Preclinical,AKT inhibitor,targeted cancer
spiradoline,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,1,Phase 2,opioid receptor agonist,noncancer
digitoxin,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CCC5C4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C,1,Launched,ATPase inhibitor,Unknown
telotristat-ethyl,CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1,1,Launched,tryptophan hydroxylase inhibitor,noncancer
bendazac,OC(=O)COc1nn(Cc2ccccc2)c2ccccc12,0,Launched,cyclooxygenase inhibitor,noncancer
pimecrolimus,CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC,0,Launched,calcineurin inhibitor,noncancer
ornidazole,Cc1ncc(n1CC(O)CCl)[N+]([O-])=O,0,Launched,antiprotozoal agent,noncancer
aztreonam,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O,1,Launched,bacterial cell wall synthesis inhibitor,noncancer
taxifolin,O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1,0,Phase 2,opioid receptor antagonist,noncancer
GSK-3-inhibitor-IX,O\N=C1/C(Nc2ccccc12)=C1/C(=O)Nc2cc(Br)ccc12,1,Preclinical,"glycogen synthase kinase inhibitor, lipoxygenase inhibitor",targeted cancer
zaleplon,CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N,1,Launched,benzodiazepine receptor agonist,noncancer
itacitinib,Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12,0,Phase 2,JAK inhibitor,targeted cancer
sotrastaurin,CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1,0,Phase 2,PKC inhibitor,targeted cancer
verubulin,COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12,1,Phase 2,tubulin polymerization inhibitor,chemo
paraxanthine,Cn1cnc2[nH]c(=O)n(C)c(=O)c12,0,Phase 1,adenosine receptor antagonist,noncancer
"ICI-118,551",CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12,0,Phase 2,adrenergic receptor antagonist,noncancer
bucetin,CCOc1ccc(NC(=O)CC(C)O)cc1,0,Withdrawn,analgesic agent,noncancer
CK-636,Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1,0,Preclinical,actin related protein inhibitor,noncancer
HA-966-(R)-(+),N[C@@H]1CCN(O)C1=O,0,Preclinical,glutamate receptor agonist,noncancer
methylnaltrexone,C[N@@+]1(CC2CC2)CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@@]3(O)CCC4=O)ccc5O,0,Launched,opioid receptor antagonist,noncancer
lidocaine,CCN(CC)CC(=O)Nc1c(C)cccc1C,1,Launched,histamine receptor agonist,noncancer
AVL-292,COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1,1,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,targeted cancer
daucosterol,CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C,0,Phase 2,apoptosis stimulant,targeted cancer
PNU-22394,Cn1c2CCNCCc2c2ccccc12,0,Phase 2,serotonin receptor agonist,noncancer
pterostilbene,COc1cc(OC)cc(C=Cc2ccc(O)cc2)c1,1,Phase 2/Phase 3,"cyclooxygenase inhibitor, PPAR receptor agonist",targeted cancer
acamprosate,CC(=O)NCCCS(O)(=O)=O,0,Launched,glutamate receptor antagonist,noncancer
diphenidol,OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor agonist,noncancer
ambenonium,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl,0,Launched,cholinesterase inhibitor,noncancer
erlotinib,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,1,Launched,EGFR inhibitor,targeted cancer
dexamethasone-sodium-phosphate,C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O,0,Launched,glucocorticoid receptor agonist,noncancer
JTE-907,CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12,0,Phase 1,cannabinoid receptor inverse agonist,noncancer
testolactone,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CCC(=O)O2,0,Launched,aromatase inhibitor,targeted cancer
hydrocortisone-valerate,CCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@]12C)C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer
trimethoprim,COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,0,Launched,dihydrofolate reductase inhibitor,noncancer
prilocaine,CCCNC(C)C(=O)Nc1ccccc1C,0,Launched,local anesthetic,noncancer
sulfacetamide,CC(=O)NS(=O)(=O)c1ccc(N)cc1,0,Launched,PABA antagonist,noncancer
YM-976,CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1,1,Phase 1,phosphodiesterase inhibitor,noncancer
cholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,0,Launched,bile acid,noncancer
cefetamet,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
clobetasol-propionate,CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl,1,Launched,glucocorticoid receptor agonist,noncancer
RHC-80267,O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1,0,Preclinical,triacylglycerol lipase inhibitor,noncancer
NU-7026,O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1,0,Preclinical,"DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor",targeted cancer
elbasvir,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,0,Launched,HCV inhibitor,noncancer
T-0070907,[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1,0,Preclinical,PPAR receptor antagonist,noncancer
doxylamine,CN(C)CCOC(C)(c1ccccc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer
5-methylfurmethiodide,Cc1ccc(C[N+](C)(C)C)o1,0,Preclinical,acetylcholine receptor agonist,noncancer
adiphenine,CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
masoprocol,CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1,0,Launched,lipoxygenase inhibitor,noncancer
TTNPB,C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C,0,Phase 1,retinoid receptor agonist,noncancer
wnt-c59,Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1,0,Preclinical,porcupine inhibitor,targeted cancer
diphenhydramine,CN(C)CCOC(c1ccccc1)c1ccccc1,0,Launched,histamine receptor antagonist,noncancer
triclabendazole,CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1,1,Launched,microtubule inhibitor,noncancer
benzotript,OC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1,0,Phase 1,CCK receptor antagonist,noncancer
JNJ-42165279,FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1,0,Phase 2,FAAH inhibitor,noncancer
dantrolene,[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1,0,Launched,calcium channel blocker,noncancer
iohexol,CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,0,Launched,radiopaque medium,Unknown
phenserine,CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21,0,Phase 3,"acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor",noncancer
iniparib,NC(=O)c1ccc(I)c(c1)[N+]([O-])=O,0,Phase 3,PARP inhibitor,targeted cancer
gadobutrol,OCC(O)[C@@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2,0,Launched,radiopaque medium,noncancer
SPP301,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1,0,Phase 3,endothelin receptor antagonist,noncancer
lacitol,OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO,1,Launched,osmosis stimulant,noncancer
AMG-208,COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1,1,Phase 1,tyrosine kinase inhibitor,targeted cancer
miglustat,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,0,Launched,Glycosyl transferase inhibitor,noncancer
mavoglurant,COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1,0,Phase 2,glutamate receptor antagonist,noncancer
WB-4101,COc1cccc(OC)c1OCCNCC1COc2ccccc2O1,0,Preclinical,adrenergic receptor antagonist,noncancer
AKBA,C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C,0,Phase 3,lipoxygenase inhibitor,targeted cancer
butenafine,CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12,0,Launched,fungal squalene epoxidase inhibitor,noncancer
L-methionine,CSCC[C@H](N)C(O)=O,0,Launched,voltage-gated calcium channel ligand,noncancer
pasireotide,NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1,0,Launched,somatostatin receptor agonist,noncancer
hydroxyzine,OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,0,Launched,antihistamine,noncancer
trioxsalen,Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1,0,Launched,DNA synthesis inhibitor,noncancer
olanzapine,CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",Unknown
AZ191,COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1,0,Preclinical,DYRK inhibitor,targeted cancer
PF-04136309,O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1,1,Phase 2,CC chemokine receptor antagonist,targeted cancer
benproperine,CC(COc1ccccc1Cc1ccccc1)N1CCCCC1,0,Launched,antitussive,noncancer
ribociclib,CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1,1,Launched,CDK inhibitor,targeted cancer
cilostamide,CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1,1,Preclinical,phosphodiesterase inhibitor,targeted cancer
trepibutone,CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O,0,Launched,cholinergic receptor antagonist,noncancer
lorlatinib,C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N,1,Phase 2,ALK tyrosine kinase receptor inhibitor,Unknown
lumiracoxib,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1,0,Withdrawn,cyclooxygenase inhibitor,noncancer
JDTic,CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1,0,Phase 1,opioid receptor antagonist,noncancer
tafenoquine,COc1cc(C)c2c(Oc3cccc(c3)C(F)(F)F)c(OC)cc(NC(C)CCCN)c2n1,0,Phase 3,antimalarial agent,noncancer
thiamphenicol,CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
"3,3'-dichlorobenzaldazine",Clc1cccc(c1)\C=N\N=C\c1cccc(Cl)c1,0,Preclinical,glutamate receptor allosteric ligand,noncancer
tonabersat,CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1,0,Phase 2,"gap junction modulator, nitric oxide production inhibitor",noncancer
rifamycin-sv,CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c(O)c2c(O)c3C,0,Phase 3,RNA synthesis inhibitor,noncancer
zileuton,CC(N(O)C(N)=O)c1cc2ccccc2s1,0,Launched,"leukotriene synthesis inhibitor, lipoxygenase inhibitor",noncancer
clobutinol,CC(CN(C)C)C(C)(O)Cc1ccc(Cl)cc1,1,Withdrawn,antitussive,noncancer
efavirenz,FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1,0,Launched,HIV protease inhibitor,noncancer
taltobulin,CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@@H](C(C)C)\C=C(/C)C(O)=O)C(C)(C)C)C(C)(C)c1ccccc1,1,Phase 1,tubulin polymerization inhibitor,chemo
troglitazone,Cc1c(C)c2OC(C)(COc3ccc(CC4SC(=O)NC4=O)cc3)CCc2c(C)c1O,0,Withdrawn,"insulin sensitizer, PPAR receptor agonist",targeted cancer
BAY-11-7085,CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N,1,Preclinical,NFkB pathway inhibitor,targeted cancer
etosalamide,CCOCCOc1ccccc1C(N)=O,0,Preclinical,anti-inflammatory agent,noncancer
chlorambucil,OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,1,Launched,DNA inhibitor,chemo
dexfosfoserine,N[C@@H](COP(O)(O)=O)C(O)=O,0,Preclinical,membrane integrity inhibitor,noncancer
quetiapine,OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
sodium-gualenate,CC(C)c1ccc(C)c2c(cc(C)c2c1)S(O)(=O)=O,0,Launched,antacid,noncancer
LY2365109,CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O,0,Preclinical,Glycine transporter 1 inhibitor,Unknown
favipiravir,NC(=O)c1nc(F)cnc1O,1,Phase 3,RNA polymerase inhibitor,noncancer
5'-Chloro-5'-deoxy-ENBA-(+/-),O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(NC3CC4CCC3C4)ncnc12,0,Preclinical,adenosine receptor agonist,Unknown
cyclocytidine,OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O,1,Preclinical,"DNA synthesis inhibitor, RNA synthesis inhibitor",chemo
mitoflaxone,OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1,0,Phase 2,antitumor agent,targeted cancer
4-chlorophenylguanidine,NC(=N)Nc1ccc(Cl)cc1,1,Preclinical,urokinase inhibitor,noncancer
LFM-A13,CC(=O)C(C#N)C(=O)Nc1cc(Br)ccc1Br,0,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,targeted cancer
tofogliflozin,CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1,1,Launched,sodium/glucose cotransporter inhibitor,noncancer
AD-5467,CC(C)C1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C,0,Phase 2,aldose reductase inhibitor,noncancer
peramivir,CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O,0,Launched,neuraminidase inhibitor,noncancer
isovaleramide,CC(C)CC(N)=O,0,Phase 2,alcohol dehydrogenase inhibitor,noncancer
mesoridazine,CN1CCCCC1CCN1c2ccccc2Sc2ccc(cc12)S(C)=O,1,Launched,dopamine receptor antagonist,noncancer
SB-216763,Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12,0,Preclinical,glycogen synthase kinase inhibitor,noncancer
PPT,CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1,1,Preclinical,estrogen receptor agonist,noncancer
zonisamide,NS(=O)(=O)Cc1noc2ccccc12,0,Launched,"sodium channel blocker, T-type calcium channel blocker",noncancer
refametinib,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,1,Phase 2,MEK inhibitor,targeted cancer
FG-2216,OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O,0,Phase 2,hypoxia inducible factor prolyl hydroxylase inhibitor,noncancer
SB-222200,CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1,0,Preclinical,tachykinin antagonist,Unknown
epirubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,1,Launched,topoisomerase inhibitor,Unknown
OLDA,CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1,1,Preclinical,TRPV agonist,noncancer
alizapride,COc1cc2[nH]nnc2cc1C(=O)NCC1CCCN1CC=C,0,Launched,dopamine receptor antagonist,noncancer
GR-159897,COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1,0,Preclinical,tachykinin antagonist,noncancer
isoconazole,Clc1ccc(C(Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1,0,Launched,fungal lanosterol demethylase inhibitor,noncancer
rheochrysidin,COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1,1,Preclinical,protein tyrosine kinase inhibitor,targeted cancer
ampicillin,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
linsidomine,Nc1c[n+](no1)N1CCOCC1,0,Launched,nitric oxide donor,noncancer
INCB-3284,COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F,0,Phase 2,CC chemokine receptor antagonist,noncancer
rimcazole,C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1,0,Phase 1,sigma receptor antagonist,targeted cancer
PF-06463922,CC1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N,0,Phase 2,ALK tyrosine kinase receptor inhibitor,targeted cancer
otenzepad,CCN(CC)CC1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12,0,Phase 3,acetylcholine receptor antagonist,noncancer
hexachlorophene,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,1,Launched,potassium channel activator,Unknown
marimastat,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,1,Phase 3,matrix metalloprotease inhibitor,targeted cancer
vorapaxar,CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1,0,Launched,thrombin receptor antagonist,noncancer
zoxazolamine,Nc1nc2cc(Cl)ccc2o1,0,Phase 2,myorelaxant,noncancer
ospemifene,OCCOc1ccc(cc1)C(\c1ccccc1)=C(\CCCl)c1ccccc1,0,Launched,selective estrogen receptor modulator (SERM),noncancer
choline,C[N+](C)(C)CCO,0,Phase 3,acetylcholine precursor,noncancer
4-P-PDOT,CCC(=O)NC1CC(c2ccccc2)c2ccccc2C1,0,Preclinical,melatonin receptor antagonist,noncancer
trimetozine,COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1,0,Launched,sedative,noncancer
AZD8330,Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O,1,Phase 1,MEK inhibitor,targeted cancer
olopatadine,CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12,0,Launched,histamine receptor antagonist,noncancer
puerarin,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O,0,Phase 2,serotonin receptor antagonist,noncancer
bedaquiline,COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12,0,Launched,ATPase inhibitor,noncancer
chlorotrianisene,COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1,0,Launched,estrogenic hormone,targeted cancer
letermovir,COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F,0,Phase 3,CMV terminase inhibitor,noncancer
BMS-265246,CCCCOc1c(cnc2[nH]ncc12)C(=O)c1c(F)cc(C)cc1F,1,Preclinical,CDK inhibitor,targeted cancer
nalidixic-acid,CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12,0,Launched,bacterial DNA gyrase inhibitor,noncancer
mofezolac,COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1,0,Launched,cyclooxygenase inhibitor,noncancer
5-BDBD,Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21,0,Preclinical,purinergic receptor antagonist,noncancer
iobenguane,NC(=N)NCc1cccc(I)c1,1,Launched,antineoplastic agent,targeted cancer
semapimod,NC(=N)NNC(=C)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(=C)NNC(N)=N)C(=C)NNC(N)=N)cc(c1)C(=C)NNC(N)=N,0,Phase 2,"cytokine production inhibitor, p38 MAPK inhibitor",targeted cancer
prulifloxacin,CC1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1,0,Launched,bacterial DNA gyrase inhibitor,noncancer
chlorhexidine,Clc1ccc(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)cc1,1,Launched,membrane integrity inhibitor,noncancer
AG-14361,CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23,1,Preclinical,PARP inhibitor,targeted cancer
azimilide,CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1,0,Phase 3,potassium channel blocker,Unknown
AZD8931,CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC,1,Phase 2,EGFR inhibitor,targeted cancer
schisandrol-b,COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC,0,Phase 3,lipid peroxidase inhibitor,Unknown
carbimazole,CCOC(=O)n1ccn(C)c1=S,0,Launched,antithyroid agent,noncancer
difluprednate,CCCC(=O)O[C@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@]3(F)[C@H](O)C[C@]12C)C(=O)COC(C)=O,1,Launched,glucocorticoid receptor agonist,noncancer
BU226,C1CN=C(N1)c1cc2ccccc2cn1,0,Preclinical,imidazoline receptor ligand,noncancer
enflurane,FC(F)OC(F)(F)C(F)Cl,0,Launched,membrane permeability inhibitor,noncancer
zatebradine,COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC,0,Phase 3,HCN channel blocker,noncancer
HMN-214,COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1,1,Phase 1,PLK inhibitor,Unknown
norfloxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1,1,Launched,bacterial DNA gyrase inhibitor,noncancer
glimepiride,CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O,0,Launched,insulin secretagogue,noncancer
10-hydroxycamptothecin,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O,1,Preclinical,topoisomerase inhibitor,Unknown
BADGE,CC(C)(c1ccc(OCC2CO2)cc1)c1ccc(OCC2CO2)cc1,0,Preclinical,PPAR receptor antagonist,targeted cancer
clofazimine,CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1,1,Launched,GK0582 inhibitor,noncancer
SKA-31,Nc1nc2c(ccc3ccccc23)s1,0,Preclinical,potassium channel activator,noncancer
2-pyridylethylamine,NCCc1ccccn1,0,Preclinical,histamine receptor agonist,noncancer
frovatriptan,CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O,0,Launched,serotonin receptor agonist,noncancer
CYC116,Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1,1,Phase 1,Aurora kinase inhibitor,targeted cancer
niguldipine-(S)-(+),COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1,0,Preclinical,adrenergic receptor antagonist,noncancer
indapamide,CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,0,Launched,thiazide diuretic,noncancer
medica-16,CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O,0,Phase 2,ATP citrase lyase inhibitor,noncancer
"ICI-215,001",O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1,0,Preclinical,adrenergic receptor agonist,noncancer
KBG,OC1O[C@@H]2COC(O[C@H]2[C@H](O)[C@H]1O)c1ccccc1,0,Phase 2,neprilysin inhibitor,targeted cancer
cinacalcet,C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12,1,Launched,calcium channel activator,Unknown
sotagliflozin,CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1,0,Phase 3,sodium/glucose cotransporter inhibitor,noncancer
N-methylquipazine,CN1CCN(CC1)c1ccc2ccccc2n1,0,Preclinical,serotonin receptor agonist,noncancer
irsogladine,Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl,0,Launched,phosphodiesterase inhibitor,noncancer
PF-03049423,CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1,0,Phase 2,phosphodiesterase inhibitor,noncancer
pentagastrin,CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,1,Launched,CCK receptor agonist,noncancer
navarixin,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,1,Phase 2,CC chemokine receptor antagonist,targeted cancer
rolipram-R(-),COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1,0,Preclinical,phosphodiesterase inhibitor,noncancer
spiroxatrine,O=C1NCN(c2ccccc2)C11CCN(CC2COc3ccccc3O2)CC1,0,Preclinical,serotonin receptor antagonist,noncancer
medetomidine,CC(c1c[nH]cn1)c1cccc(C)c1C,0,Launched,adrenergic receptor agonist,noncancer
FH1,CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1,0,Preclinical,hepatocyte function enhancer,noncancer
otilonium,CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC,0,Launched,acetylcholine receptor antagonist,noncancer
MM77,COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1,0,Preclinical,serotonin receptor antagonist,Unknown
nefazodone,CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1,0,Withdrawn,"adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor",noncancer
enprofylline,CCCn1c2nc[nH]c2c(=O)[nH]c1=O,0,Phase 3,phosphodiesterase inhibitor,noncancer
apricitabine,Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1,0,Phase 3,nucleoside reverse transcriptase inhibitor,noncancer
YM-201636,Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1,1,Preclinical,PI3K inhibitor,targeted cancer
ditiocarb-sodium-trihydrate,CCN(CC)C(S)=S,0,Phase 3,immunostimulant,noncancer
avobenzone,COc1ccc(cc1)C(=O)CC(=O)c1ccc(cc1)C(C)(C)C,0,Launched,UV blocker,Unknown
hydroquinidine,CC[C@H]1CN2CCC1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,0,Launched,antiarrhythmic,noncancer
LY411575,C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O,0,Preclinical,gamma secretase inhibitor,noncancer
benfluorex,CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1,0,Withdrawn,gluconeogenesis inhibitor,noncancer
TAS-103,CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12,1,Phase 1,topoisomerase inhibitor,chemo
betamipron,OC(=O)CCNC(=O)c1ccccc1,0,Launched,panipenem uptake inhibitor,noncancer
alosetron,Cc1[nH]cnc1CN1CCc2c(C1=O)c1ccccc1n2C,0,Withdrawn,serotonin receptor antagonist,noncancer
apoptosis-activator-II,Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl,0,Preclinical,carboxylesterase inhibitor,noncancer
cyclovirobuxin-d,CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C,1,Preclinical,calcium channel modulator,noncancer
alvespimycin,CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O,1,Phase 2,HSP inhibitor,targeted cancer
tryptophan,N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O,0,Launched,serotonin receptor partial agonist,noncancer
HA14-1,CCOC(=O)[C@@H](C#N)[C@@H]1c2cc(Br)ccc2OC(N)=C1C(=O)OCC,1,Preclinical,BCL inhibitor,targeted cancer
napabucasin,CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O,1,Phase 3,STAT inhibitor,targeted cancer
limaprost-alfadex,CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O,0,Launched,prostanoid receptor agonist,noncancer
riociguat,COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12,1,Launched,guanylate cyclase stimulant,noncancer
odanacatib,CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N,1,Phase 3,cathepsin inhibitor,targeted cancer
FPA-124,Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O,0,Preclinical,AKT inhibitor,Unknown
tacalcitol,CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,1,Launched,vitamin D receptor agonist,noncancer
tyrphostin-AG-835,C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1,0,Preclinical,protein tyrosine kinase inhibitor,targeted cancer
talampanel,C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1,0,Phase 2,glutamate receptor antagonist,targeted cancer
2-iodomelatonin,COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1,0,Preclinical,melatonin receptor agonist,noncancer
SANT-2,CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1,0,Preclinical,smoothened receptor antagonist,targeted cancer
dexchlorpheniramine,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer
halothane,FC(F)(F)C(Cl)Br,0,Launched,glutamate receptor antagonist,noncancer
bardoxolone,CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O,1,Phase 1,"nuclear factor erythroid derived, like (NRF2) activator",targeted cancer
A-803467,COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1,1,Preclinical,sodium channel blocker,noncancer
brexpiprazole,O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1,0,Launched,dopamine receptor partial agonist,noncancer
leteprinim,OC(=O)c1ccc(NC(=O)CCn2cnc3c(O)ncnc23)cc1,0,Phase 2,nerve growth factor agonist,targeted cancer
pyronaridine,COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1,0,Phase 3,antimalarial agent,noncancer
voriconazole,C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,0,Launched,cytochrome P450 inhibitor,Unknown
rosoxacin,CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1,0,Launched,topoisomerase inhibitor,noncancer
levomepromazine,COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1,0,Launched,dopamine receptor antagonist,noncancer
avagacestat,NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1,0,Phase 2,gamma secretase inhibitor,noncancer
CX-5461,CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O,1,Phase 1,RNA polymerase inhibitor,targeted cancer
talnetant,CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1,0,Phase 2,tachykinin antagonist,noncancer
sulfachlorpyridazine,Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1,0,Launched,bacterial antifolate,noncancer
acrivastine,Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1,0,Launched,histamine receptor antagonist,noncancer
nifenalol,CC(C)NCC(O)c1ccc(cc1)[N+]([O-])=O,0,Launched,adrenergic receptor antagonist,noncancer
7-chlorokynurenic-acid,OC(=O)c1cc(O)c2ccc(Cl)cc2n1,0,Preclinical,glutamate receptor antagonist,noncancer
tolazamide,Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1,0,Launched,ATP channel blocker,noncancer
cebranopadol,CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1,1,Phase 3,opioid receptor agonist,noncancer
LY456236,COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1,1,Preclinical,glutamate receptor antagonist,noncancer
daclatasvir,COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C,1,Launched,HCV inhibitor,noncancer
dalargin,CC(C)CC(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)C(N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O,0,Phase 2,opioid receptor agonist,noncancer
hyoscyamine,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1,1,Launched,acetylcholine receptor antagonist,noncancer
PRIMA1,OCC1(CO)N2CCC(CC2)C1=O,0,Preclinical,TP53 inhibitor,targeted cancer
dimemorfan,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31,0,Launched,sigma receptor agonist,noncancer
estetrol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O,0,Phase 3,selective estrogen receptor modulator (SERM),targeted cancer
OTS167,CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O,1,Phase 1,maternal embryonic leucine zipper kinase inhibitor,Unknown
UNC0646,COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
atenolol-(-),CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1,1,Phase 2,adrenergic receptor antagonist,noncancer
clorgiline,CN(CCCOc1ccc(Cl)cc1Cl)CC#C,0,Phase 2,monoamine oxidase inhibitor,Unknown
TCS-359,COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O,0,Preclinical,FLT3 inhibitor,targeted cancer
paroxetine,Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1,0,Launched,selective serotonin reuptake inhibitor (SSRI),noncancer
adiporon,O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1,0,Preclinical,adiponectin receptor agonist,targeted cancer
olaparib,Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1,1,Launched,PARP inhibitor,targeted cancer
Y-26763,CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,0,Phase 1,potassium channel activator,noncancer
darapladib,CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1,1,Phase 3,phospholipase inhibitor,noncancer
tapentadol,CC[C@@H]([C@@H](C)CN(C)C)c1cccc(O)c1,0,Launched,opioid receptor agonist,Unknown
7-aminocephalosporanic-acid,CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O,1,Preclinical,beta lactamase inhibitor,noncancer
dexniguldipine,COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1,0,Phase 2,calmodulin antagonist,targeted cancer
dizocilpine-(+),C[C@]12N[C@H](Cc3ccccc13)c1ccccc21,0,Preclinical,glutamate receptor antagonist,noncancer
R547,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N,1,Phase 1,CDK inhibitor,Unknown
SN-38,CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12,1,Launched,topoisomerase inhibitor,Unknown
flupentixol,OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1,0,Launched,dopamine receptor antagonist,noncancer
tubocurarine,COc1cc2CCN(C)[C@H]3Cc4ccc(Oc5c(O)c(OC)cc6CC[N+](C)(C)[C@H](Cc7ccc(O)c(Oc1cc23)c7)c56)cc4,0,Launched,acetylcholine receptor antagonist,Unknown
pentostatin,OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CNC=Nc12,1,Launched,"adenosine deaminase inhibitor, ribonucleotide reductase inhibitor",chemo
E-4031,Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1,0,Phase 1,potassium channel blocker,noncancer
alectinib,CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1,1,Launched,ALK tyrosine kinase receptor inhibitor,targeted cancer
gestodene,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C,0,Launched,contraceptive agent,noncancer
phenytoin,O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1,0,Launched,hydantoin antiepileptic,noncancer
indobufen,CCC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,0,Launched,"cyclooxygenase inhibitor, platelet aggregation inhibitor",noncancer
chlormadinone-acetate,CC(=O)O[C@@]1(CCC2C3C=C(Cl)C4=CC(=O)CC[C@]4(C)C3CC[C@]12C)C(C)=O,0,Launched,5 alpha reductase inhibitor,noncancer
difenpiramide,O=C(Cc1ccc(cc1)-c1ccccc1)Nc1ccccn1,0,Launched,"cyclooxygenase inhibitor, prostaglandin inhibitor",noncancer
ketorolac,OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
tiaprofenic-acid,CC(C(O)=O)c1ccc(s1)C(=O)c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
PETCM,OC(Cc1ccncc1)C(Cl)(Cl)Cl,1,Preclinical,caspase activator,noncancer
abiraterone-acetate,CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1,1,Launched,androgen biosynthesis inhibitor,targeted cancer
chromanol-(+/-),CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N,0,Preclinical,potassium channel blocker,Unknown
sulfapyridine,Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1,0,Launched,PABA antagonist,noncancer
gavestinel,OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1,0,Phase 3,glutamate receptor antagonist,noncancer
PD-168393,Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,1,Preclinical,EGFR inhibitor,targeted cancer
meisoindigo,CN1C(=O)\C(c2ccccc12)=C1\C(=O)Nc2ccccc12,0,Phase 3,STAT inhibitor,targeted cancer
lazabemide,NCCNC(=O)c1ccc(Cl)cn1,0,Phase 3,monoamine oxidase inhibitor,noncancer
mestinon,CN(C)C(=O)Oc1ccc[n+](C)c1,0,Launched,cholinesterase inhibitor,noncancer
chicago-sky-blue-6b,COc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1,1,Preclinical,"glutamate inhibitor, macrophage migration inhibiting factor inhibitor",noncancer
dideoxyadenosine,Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1,0,Phase 1,nucleoside reverse transcriptase inhibitor,noncancer
trimebutine,CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1,1,Launched,opioid receptor agonist,noncancer
tagatose,OCC(O)C(O)C(O)C(=O)CO,1,Phase 3,phosphorylase inhibitor,noncancer
piricapiron,CC1(C)C2CCC1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O,0,Phase 2,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
amantadine,NC12CC3CC(CC(C3)C1)C2,0,Launched,glutamate receptor antagonist,noncancer
BMS-587101,CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1,0,Phase 2,integrin antagonist,noncancer
3-carboxy-4-hydroxyphenylglycine-(S),N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O,0,Preclinical,glutamate receptor antagonist,noncancer
UNC0224,COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
levo-phencynonate,CN1CC2CCCC(C1)C2OC(=O)C(O)(C1CCCC1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,1,Launched,estrogen receptor agonist,noncancer
selamectin,CO[C@H]1CC(O[C@H]2[C@@H](C)\C=C\C=C3/CO[C@@H]4C(=N/O)\C(C)=C[C@@H](C(=O)O[C@H]5C[C@@H](C\C=C2/C)O[C@@]2(CC[C@H](C)[C@H](O2)C2CCCCC2)C5)[C@]34O)O[C@@H](C)C1O,1,Launched,nematocide,noncancer
Z160,O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1,0,Phase 2,N-type calcium channel blocker,noncancer
acetohydroxamic-acid,CC(=O)NO,0,Launched,urease inhibitor,noncancer
chlorogenic-acid,O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O,1,Launched,antioxidant,noncancer
articaine,CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,0,Launched,local anesthetic,Unknown
clotrimazole,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,1,Launched,"cytochrome P450 inhibitor, imidazoline receptor ligand",noncancer
nimorazole,[O-][N+](=O)c1cncn1CCN1CCOCC1,1,Launched,bacterial DNA inhibitor,targeted cancer
dalfampridine,Nc1ccncc1,0,Launched,potassium channel blocker,noncancer
exalamide,CCCCCCOc1ccccc1C(N)=O,0,Launched,membrane permeability inhibitor,noncancer
demecarium,CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C,1,Launched,acetylcholinesterase inhibitor,noncancer
SK&F-10047-(+),C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C,0,Phase 1,sigma receptor agonist,noncancer
terfenadine,CC(C)(C)c1ccc(cc1)C(O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1,1,Withdrawn,histamine receptor antagonist,noncancer
lycopene,CC(C)=CCC\C(C)=C\C=C\C(C)=C\C=C\C(C)=C\C=C\C=C(C)\C=C\C=C(C)\C=C\C=C(/C)CCC=C(C)C,0,Phase 3,free radical scavenger,noncancer
rimexolone,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,1,Launched,glucocorticoid receptor agonist,noncancer
nalmefene,Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O,0,Launched,opioid receptor antagonist,noncancer
ergocalciferol,CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C,0,Launched,vitamin analog,noncancer
ATN-161,CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O,0,Phase 2,integrin antagonist,targeted cancer
GW-405833,COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1,1,Preclinical,cannabinoid receptor agonist,noncancer
salicin,OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O,0,Phase 1,anti-inflammatory agent,noncancer
carazolol,CC(C)NCC(O)COc1cccc2[nH]c3ccccc3c12,0,Launched,adrenergic receptor antagonist,noncancer
ozanimod,CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO,0,Phase 3,sphingosine 1 phosphate receptor agonist,noncancer
rosiglitazone,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,0,Withdrawn,"insulin sensitizer, PPAR receptor agonist",noncancer
leuprolide,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,0,Launched,gonadotropin releasing factor hormone receptor agonist,targeted cancer
purmorphamine,C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12,0,Preclinical,smoothened receptor agonist,noncancer
buparvaquone,CC(C)(C)C1CCC(CC2C(=O)C(=O)c3ccccc3C2=O)CC1,0,Launched,antiprotozoal agent,noncancer
L-701324,Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12,0,Preclinical,glutamate receptor antagonist,noncancer
dimercaprol,OCC(S)CS,0,Launched,chelating agent,noncancer
abametapir,Cc1ccc(nc1)-c1ccc(C)cn1,0,Phase 3,metalloproteinase inhibitor,noncancer
cariprazine,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1,0,Launched,dopamine receptor antagonist,noncancer
entrectinib,CN1CCN(CC1)c1ccc(C(=O)Nc2n[nH]c3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1,0,Phase 2,"ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor",targeted cancer
methyldopa,C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O,1,Launched,adrenergic receptor agonist,noncancer
clinofibrate,CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(OC(C)(CC)C(O)=O)cc1)C(O)=O,0,Launched,lipase clearing factor inhibitor,noncancer
flopropione,CCC(=O)c1c(O)cc(O)cc1O,0,Launched,serotonin receptor antagonist,noncancer
paroxypropione,CCC(=O)c1ccc(O)cc1,0,Launched,gonadotropin inhibitor,noncancer
azodicarbonamide,NC(=O)\N=N\C(N)=O,1,Phase 2,DNA synthesis inhibitor,noncancer
bifonazole,c1cn(cn1)C(c1ccccc1)c1ccc(cc1)-c1ccccc1,0,Launched,sterol demethylase inhibitor,noncancer
MPI-0479605,Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1,1,Preclinical,mitotic kinase inhibitor,targeted cancer
deferoxamine-mesylate,CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,0,Launched,chelating agent,noncancer
tracazolate,CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12,0,Phase 2,GABA receptor modulator,noncancer
YS-035,COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC,0,Preclinical,calcium channel blocker,noncancer
chenodeoxycholic-acid,C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Launched,"11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist",noncancer
LY255283,CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nnn[nH]1,0,Preclinical,leukotriene receptor antagonist,noncancer
diperodon,O=C(Nc1ccccc1)OCC(CN1CCCCC1)OC(=O)Nc1ccccc1,0,Preclinical,local anesthetic,noncancer
tyrphostin-A9,CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C,1,Preclinical,"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor",targeted cancer
halofuginone,O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O,1,Launched,collagenase inhibitor,Unknown
eperisone,CCc1ccc(cc1)C(=O)C(C)CN1CCCCC1,0,Launched,acetylcholine receptor antagonist,noncancer
PNU-120596,COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl,0,Preclinical,acetylcholine receptor agonist,noncancer
AZD9668,Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C,1,Phase 2,elastase inhibitor,noncancer
carisoprodol,CCCC(C)(COC(N)=O)COC(=O)NC(C)C,0,Launched,acetylcholine receptor antagonist,noncancer
imidafenacin,Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
BRL-37344,C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1,0,Phase 2,adrenergic receptor agonist,noncancer
KT-433,CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1,0,Phase 2,uricosuric agent,noncancer
cardiogenol-c,COc1ccc(Nc2nccc(NCCO)n2)cc1,0,Preclinical,cardiomyogenesis inducer,Unknown
lomitapide,FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12,1,Launched,microsomal trigylceride transfer protein inhibitor,noncancer
valrubicin,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1,1,Launched,"DNA inhibitor, topoisomerase inhibitor",chemo
amcinonide,CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1CC1C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C,0,Launched,glucocorticoid receptor agonist,noncancer
indirubin-3-monoxime,O\N=C1c2ccccc2NC/1=C1\C(=O)Nc2ccccc12,0,Preclinical,"CDK inhibitor, glycogen synthase kinase inhibitor",targeted cancer
foscarnet,OC(=O)P(O)(O)=O,1,Launched,DNA polymerase inhibitor,noncancer
GDC-0810,CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,0,Phase 2,selective estrogen receptor destabilizer,targeted cancer
zolmitriptan,CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12,1,Launched,serotonin receptor agonist,noncancer
BIIB021,COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C,1,Phase 2,HSP inhibitor,Unknown
norgestrel,CC[C@]12CCC3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,1,Launched,progesterone receptor agonist,noncancer
celecoxib,Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F,0,Launched,cyclooxygenase inhibitor,noncancer
TWS-119,Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1,1,Preclinical,glycogen synthase kinase inhibitor,noncancer
methylprednisolone-aceponate,CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O,0,Launched,"anti-inflammatory agent, glucocorticoid receptor agonist",noncancer
somatostatin,C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC1=O)[C@@H](C)O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N,0,Launched,somatostatin receptor agonist,noncancer
L-Cysteinesulfinic-acid,N[C@@H](CS(O)=O)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer
temsirolimus,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO,1,Launched,mTOR inhibitor,targeted cancer
cyclizine,CN1CCN(CC1)C(c1ccccc1)c1ccccc1,0,Launched,histamine receptor modulator,noncancer
hydroxyamphetamine,CC(N)Cc1ccc(O)cc1,0,Launched,trace amine associated receptor agonist,noncancer
enoximone,CSc1ccc(cc1)C(=O)c1[nH]c(O)nc1C,1,Launched,phosphodiesterase inhibitor,noncancer
apafant,Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl,0,Phase 3,platelet activating factor receptor antagonist,noncancer
caffeine,Cn1cnc2n(C)c(=O)n(C)c(=O)c12,0,Launched,"adenosine receptor antagonist, phosphodiesterase inhibitor",noncancer
balsalazide,OC(=O)CCNC(=O)c1ccc(cc1)N=Nc1ccc(O)c(c1)C(O)=O,0,Launched,cyclooxygenase inhibitor,noncancer
Ro-20-1724,CCCCOc1cc(CC2CNC(=O)N2)ccc1OC,0,Preclinical,phosphodiesterase inhibitor,noncancer
nithiamide,CC(=O)Nc1ncc(s1)[N+]([O-])=O,1,Preclinical,bacterial DNA inhibitor,noncancer
GSK1292263,CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1,1,Phase 2,glucose dependent insulinotropic receptor agonist,noncancer
epoprostenol,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O,0,Launched,prostacyclin analog,noncancer
alagebrium,Cc1sc[n+](CC(=O)c2ccccc2)c1C,0,Phase 2/Phase 3,glycosylation inhibitor,noncancer
aceclidine,CC(=O)OC1CN2CCC1CC2,0,Launched,acetylcholine receptor agonist,noncancer
amygdalin,OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,0,Phase 2,caspase activator,targeted cancer
butorphanol-(+)-tartrate,Oc1ccc2C[C@H]3N(CC4CCC4)CC[C@@]4(CCCC[C@@]34O)c2c1,0,Launched,"opioid receptor agonist, opioid receptor antagonist",noncancer
FK-888,CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12,1,Phase 2,tachykinin antagonist,noncancer
diclazuril,Clc1ccc(cc1)C(C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O,1,Launched,antiprotozoal agent,noncancer
dexlansoprazole,Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,0,Launched,ATPase inhibitor,noncancer
camicinal,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1,0,Phase 2,motilin receptor agonist,noncancer
PSI-6130,C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O,0,Phase 1,RNA polymerase inhibitor,noncancer
cefepime,CO\N=C(\C(=O)NC1C2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
fenoprofen,CC(C(O)=O)c1cccc(Oc2ccccc2)c1,1,Launched,prostaglandin inhibitor,noncancer
nicaraven,CC(CNC(=O)c1cccnc1)NC(=O)c1cccnc1,0,Phase 3,free radical scavenger,noncancer
clemastine,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,0,Launched,histamine receptor antagonist,noncancer
ASC-J9,COc1ccc(cc1OC)\C=C\C(=O)CC(=O)\C=C\c1ccc(OC)c(OC)c1,0,Phase 2,androgen receptor enhancer,targeted cancer
methsuximide,CN1C(=O)CC(C)(C1=O)c1ccccc1,0,Launched,T-type calcium channel binder,noncancer
ML161,CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1,0,Preclinical,protease-activated receptor inhibitor,noncancer
oxaprozin,OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,Unknown
RN-1747,[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1,0,Preclinical,TRPV agonist,noncancer
GSK-J4,CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1,1,Preclinical,histone lysine demethylase inhibitor,targeted cancer
ibuprofen,CC(C)Cc1ccc(cc1)C(C)C(O)=O,0,Launched,cyclooxygenase inhibitor,noncancer
amonafide,CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23,1,Phase 3,topoisomerase inhibitor,chemo
betamethasone-acetate,C[C@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O,0,Launched,glucocorticoid receptor agonist,noncancer
SB-525334,Cc1cccc(n1)-c1[nH]c(nc1-c1ccc2nccnc2c1)C(C)(C)C,1,Preclinical,TGF beta receptor inhibitor,noncancer
isradipine,COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C,0,Launched,calcium channel blocker,noncancer
DMAB-anabaseine,CN(C)c1ccc(cc1)\C=C1CCCN=C/1c1cccnc1,0,Preclinical,adrenergic receptor agonist,noncancer
pexidartinib,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,0,Phase 3,tyrosine kinase inhibitor,targeted cancer
acarbose,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,0,Launched,glucosidase inhibitor,noncancer
"CP-945,598",CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O,1,Phase 3,cannabinoid receptor antagonist,noncancer
GW-9508,OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1,0,Preclinical,"free fatty acid receptor agonist, G protein-coupled receptor agonist",noncancer
PGL5001,N#CC(c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1,0,Phase 2,JNK inhibitor,noncancer
primidone,CCC1(C(=O)NCNC1=O)c1ccccc1,0,Launched,GABA receptor antagonist,noncancer
ellagic-acid,Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O,0,Phase 2,"glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor",targeted cancer
apremilast,CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O,0,Launched,phosphodiesterase inhibitor,Unknown
nTZDpa,OC(=O)c1n(Cc2ccc(Cl)cc2)c2ccc(Cl)cc2c1Sc1ccccc1,0,Preclinical,PPAR receptor agonist,noncancer
diltiazem,COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,0,Launched,calcium channel blocker,noncancer
cobimetinib,OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1,1,Launched,MEK inhibitor,targeted cancer
SN-6,CCOC(=O)C1CSC(N1)Cc1ccc(OCc2ccc([N+]([O-])=O)cc2)cc1,0,Preclinical,sodium/calcium exchange inhibitor,noncancer
canertinib,Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl,1,Phase 3,EGFR inhibitor,targeted cancer
SCMC-Lys,N[C@@H](CSCC(O)=O)C(O)=O,0,Launched,mucolytic agent,Unknown
oxyphenonium,CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1,0,Launched,cholinergic receptor antagonist,noncancer
spironolactone,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12,1,Launched,mineralocorticoid receptor antagonist,noncancer
nitrofurantoin,[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1,0,Launched,DNA inhibitor,noncancer
LY364947,c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1,1,Preclinical,"TGF beta receptor inhibitor, p38 MAPK inhibitor",targeted cancer
PD-98059,COc1cccc(-c2cc(=O)c3ccccc3o2)c1N,1,Preclinical,MEK inhibitor,targeted cancer
metyrapone,CC(C)(C(=O)c1cccnc1)c1cccnc1,1,Launched,cytochrome P450 inhibitor,noncancer
vorinostat,ONC(=O)CCCCCCC(=O)Nc1ccccc1,1,Launched,HDAC inhibitor,targeted cancer
diclofenamide,NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer
SDZ-220-581,N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O,0,Preclinical,glutamate receptor antagonist,noncancer
phenazopyridine,Nc1ccc(\N=N\c2ccccc2)c(N)n1,0,Launched,local anesthetic,noncancer
relcovaptan,COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl,0,Phase 2,vasopressin receptor antagonist,targeted cancer
delivert,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O,0,Launched,angiotensin receptor agonist,targeted cancer
fluoxetine,CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1,0,Launched,selective serotonin reuptake inhibitor (SSRI),noncancer
3-amino-benzamide,NC(=O)c1cccc(N)c1,1,Phase 2,PARP inhibitor,targeted cancer
alprenolol,CC(C)NCC(O)COc1ccccc1CC=C,0,Launched,adrenergic receptor antagonist,noncancer
10058-F4,CCc1ccc(cc1)\C=C1\SC(=S)NC1=O,0,Preclinical,c-Myc inhibitor,targeted cancer
NMDA,CN[C@H](CC(O)=O)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer
sulfamethoxypyridazine,COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1,0,Withdrawn,bacterial antifolate,noncancer
metolazone,CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer
indoprofen,CC(C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O,1,Withdrawn,"cyclooxygenase inhibitor, prostanoid receptor antagonist",noncancer
SKF-89976A,OC(=O)C1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1,0,Preclinical,GABA uptake inhibitor,noncancer
fenigam,NCC(CC(O)=O)c1ccccc1,0,Launched,benzodiazepine receptor agonist,noncancer
3-AQC,C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N,0,Preclinical,serotonin receptor agonist,noncancer
LY2608204,O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1,1,Phase 2,glucokinase activator,noncancer
buspirone,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,0,Launched,serotonin receptor agonist,Unknown
PF-03084014,CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C,0,Phase 2,gamma secretase inhibitor,targeted cancer
C-1,O=S(=O)(N1CCNCC1)c1cccc2cnccc12,0,Preclinical,protein kinase inhibitor,noncancer
PJ-34,CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1,1,Preclinical,PARP inhibitor,targeted cancer
oleamide,CCCCCCCC\C=C/CCCCCCCC(N)=O,0,Preclinical,cannabinoid receptor agonist,noncancer
AS-1949490,C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1,1,Preclinical,SHIP2 phosphatase inhibitor,noncancer
SNX-5422,CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1,1,Phase 1/Phase 2,HSP inhibitor,Unknown
benzoxiquine,O=C(Oc1cccc2cccnc12)c1ccccc1,0,Preclinical,antiinfective drug,noncancer
mesna,OS(=O)(=O)CCS,1,Launched,antioxidant,noncancer
MRS1845,CCOC(=O)C1=C(C)N(CC#C)C(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC,0,Preclinical,calcium channel blocker,noncancer
DCPIB,CCCCC1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1,0,Preclinical,"chloride channel blocker, gap junction modulator, glutamate inhibitor",noncancer
doxofylline,Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O,0,Launched,adenosine receptor antagonist,noncancer
SR-27897,OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl,1,Phase 2,CCK receptor antagonist,targeted cancer
deflazacort,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C,1,Launched,glucocorticoid receptor agonist,noncancer
AMG-9810,CC(C)(C)c1ccc(cc1)\C=C\C(=O)Nc1ccc2OCCOc2c1,0,Preclinical,TRPV antagonist,noncancer
ganciclovir,Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1,0,Launched,DNA polymerase inhibitor,noncancer
quinagolide,CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC,0,Launched,dopamine receptor agonist,noncancer
eltrombopag,CC1=NN(C(=O)C\1=N\Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1,1,Launched,thrombopoietin receptor agonist,noncancer
fiacitabine,Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,Phase 2,DNA synthesis inhibitor,noncancer
oglemilast,CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1,0,Phase 2,phosphodiesterase inhibitor,noncancer
OSI-930,FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1,1,Phase 1,"KIT inhibitor, VEGFR inhibitor",targeted cancer
SEP-227900,OC(=O)c1cc2occc2[nH]1,0,Phase 1,D-Amino Acid Oxidase Inhibitor,noncancer
BMS-626529,COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12,1,Phase 3,HIV attachment inhibitor,noncancer
benzyldimethylhexadecylammonium,CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,1,Preclinical,cationic surfactant,noncancer
propylthiouracil,CCCc1cc(=O)[nH]c(=S)[nH]1,0,Launched,thyroid peroxidase inhibitor,noncancer
tenatoprazole,COc1ccc2[nH]c(nc2n1)S(=O)Cc1ncc(C)c(OC)c1C,0,Phase 2,ATPase inhibitor,noncancer
tempol,CC1(C)CC(O)CC(C)(C)N1O,0,Phase 2,free radical scavenger,targeted cancer
bezafibrate,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O,0,Launched,PPAR receptor agonist,noncancer
ibuprofen-piconol,CC(C)Cc1ccc(cc1)C(C)C(=O)OCc1ccccn1,0,Launched,cyclooxygenase inhibitor,noncancer
amlodipine,CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC,0,Launched,calcium channel blocker,noncancer
clevudine,Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@@H]2F)c(=O)[nH]c1=O,0,Launched,DNA polymerase inhibitor,noncancer
lucitanib,CNC(=O)c1cccc2cc(ccc12)Oc1ccnc2cc(OCC3(N)CC3)c(OC)cc12,1,Phase 2,"FGFR inhibitor, VEGFR inhibitor",targeted cancer
benzocaine,CCOC(=O)c1ccc(N)cc1,1,Launched,sodium channel blocker,noncancer
nicotine,CN1CCCC1c1cccnc1,1,Launched,acetylcholine receptor agonist,noncancer
PF-05212384,CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1,1,Phase 2,"mTOR inhibitor, PI3K inhibitor",targeted cancer
bropirimine,Nc1nc(-c2ccccc2)c(Br)c(=O)[nH]1,0,Phase 3,interferon inducer,targeted cancer
lersivirine,CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N,0,Phase 2,non-nucleoside reverse transcriptase inhibitor,noncancer
diclofensine,COc1ccc2C(CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1,0,Phase 3,dopamine reuptake inhibitor,noncancer
tetrabenazine,COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC,0,Launched,vesicular monoamine transporter inhibitor,noncancer
methoxamine,COc1ccc(OC)c(c1)C(O)C(C)N,0,Launched,adrenergic receptor agonist,noncancer
REV-5901,CCCCCC(O)c1cccc(OCc2ccc3ccccc3n2)c1,0,Phase 2,"leukotriene receptor antagonist, lipoxygenase inhibitor",noncancer
SKI-II,Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1,1,Preclinical,sphingosine kinase inhibitor,targeted cancer
foretinib,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1,1,Phase 2,VEGFR inhibitor,targeted cancer
lobendazole,CCOC(=O)Nc1nc2ccccc2[nH]1,0,Preclinical,anthelmintic agent,noncancer
milacemide,CCCCCNCC(N)=O,0,Phase 3,monoamine oxidase inhibitor,noncancer
AMG-319,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1,0,Phase 2,PI3K inhibitor,targeted cancer
3-deazaneplanocin-A,Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O,1,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
procaterol,CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,0,Launched,adrenergic receptor agonist,noncancer
dronedarone,CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12,1,Launched,adrenergic receptor antagonist,noncancer
TC1,OC12C3C4C5C3C(C3C5CC4C13)N2CCc1cccc(F)c1,1,Preclinical,beta-secretase inhibitor,noncancer
WZ4003,CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1,0,Preclinical,AMPK inhibitor,noncancer
nitrocaramiphen,CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O,1,Preclinical,cholinergic receptor antagonist,noncancer
CGP-37157,Clc1ccc2NC(=O)CSC(c3ccccc3Cl)c2c1,0,Preclinical,"mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor",noncancer
terbinafine,CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12,0,Launched,fungal squalene epoxidase inhibitor,noncancer
PF-03758309,CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)n[nH]c2C1(C)C)c1ccccc1,1,Phase 1,p21 activated kinase inhibitor,targeted cancer
podophyllotoxin,COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12,1,Launched,"microtubule inhibitor, tubulin polymerization inhibitor",noncancer
nicergoline,CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13,0,Launched,adrenergic receptor antagonist,noncancer
WYE-125132,CNC(=O)Nc1ccc(cc1)-c1nc(N2CC3CCC(C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1,1,Preclinical,mTOR inhibitor,targeted cancer
hydralazine,NNc1nncc2ccccc12,0,Launched,vasodilator,noncancer
rutin,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,1,Launched,"antioxidant, capillary stabilizing agent, nitric oxide scavenger",noncancer
ethoxzolamide,CCOc1ccc2nc(sc2c1)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer
ipragliflozin-l-proline,OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1,0,Launched,sodium/glucose cotransporter inhibitor,noncancer
cloxacillin,Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
cefozopran,CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
epothilone-d,C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1,1,Phase 2,"microtubule stabilizing agent, tubulin polymerization inhibitor",chemo
tedizolid,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O,1,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
isoxsuprine,CC(COc1ccccc1)NC(C)[C@H](O)c1ccc(O)cc1,1,Launched,adrenergic receptor agonist,noncancer
tegobuvir,Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1,0,Phase 3,"HCV inhibitor, protease inhibitor",noncancer
k-strophanthidin,C[C@]12CCC3C(CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CCC2C1=CC(=O)OC1,1,Phase 2,ATPase inhibitor,targeted cancer
vatalanib,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,1,Phase 3,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
niraparib,NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1,1,Launched,PARP inhibitor,targeted cancer
mericitabine,CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C,1,Phase 2,HCV inhibitor,noncancer
urea,NC(N)=O,0,Launched,hydroxy radical formation stimulant,noncancer
SDZ-21009,CC(C)OC(=O)c1cc2c(OCC(O)CNC(C)(C)C)cccc2[nH]1,0,Preclinical,"adrenergic receptor antagonist, serotonin receptor antagonist",noncancer
iopamidol,C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I,0,Launched,radiopaque medium,noncancer
BMS-690514,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1,1,Phase 2,"EGFR inhibitor, VEGFR inhibitor",targeted cancer
camptothecin,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O,1,Phase 3,topoisomerase inhibitor,Unknown
mebeverine,CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1,0,Launched,acetylcholine receptor antagonist,noncancer
idebenone,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,0,Launched,calcium channel modulator,noncancer
pergolide,CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13,0,Withdrawn,dopamine receptor agonist,noncancer
scriptaid,ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23,1,Preclinical,HDAC inhibitor,targeted cancer
AMG-517,CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1,0,Phase 1,TRPV antagonist,noncancer
VE-821,CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1,1,Preclinical,ATR kinase inhibitor,targeted cancer
"6,_7-dehydro-17-acetoxy-progesterone",CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O,0,Preclinical,steroidal progestin,noncancer
meclocycline-sulfosalicylate,CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(C(=O)c4c(O)ccc(Cl)c4C3=C)C(=O)[C@]2(O)C(=O)C(C(N)=O)C1=O,0,Launched,bacterial 50S ribosomal subunit inhibitor,noncancer
fendiline,CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1,1,Preclinical,calcium channel blocker,noncancer
inositol,O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O,0,Launched,insulin sensitizer,noncancer
NPC-01,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O,0,Phase 3,steroid,noncancer
crizotinib-(S),C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl,1,Preclinical,MTH1 inhibitor,targeted cancer
entinostat,Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,1,Phase 3,HDAC inhibitor,targeted cancer
parthenolide,C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1,1,Phase 1,NFkB pathway inhibitor,targeted cancer
sulfafurazole,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C,0,Launched,bacterial antifolate,noncancer
suloctidil,CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1,0,Withdrawn,adrenergic receptor antagonist,noncancer
tiludronate,OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O,1,Launched,"bone resorption inhibitor, osteoclast inhibitor",noncancer
MM-102,CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1,0,Preclinical,WDR5/MLL interaction inhibitor,noncancer
UNC0638,COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
isofloxythepin,CC(C)c1ccc2Sc3cc(F)ccc3CC(N3CCN(CCO)CC3)c2c1,1,Phase 2,dopamine receptor antagonist,noncancer
hydroxychloroquine,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,0,Launched,antimalarial agent,noncancer
BW-723C86,CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12,0,Preclinical,serotonin receptor agonist,noncancer
6-chloromelatonin,COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl,0,Preclinical,melatonin receptor agonist,noncancer
blonanserin,CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
eprinomectin,CCC(C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](OC4C[C@H](OC)C(O[C@H]5C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C,1,Launched,benzodiazepine receptor agonist,noncancer
CB-10-277,CN(C)\N=N\c1ccc(cc1)C(O)=O,1,Phase 1,DNA synthesis inhibitor,chemo
RS-16566,CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1CN2CCC1CC2,1,Preclinical,serotonin receptor antagonist,noncancer
vecuronium,CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1,0,Launched,acetylcholine receptor antagonist,noncancer
CCT129202,CN(C)c1ccc(cc1)-c1nc2c(N3CCN(CC(=O)Nc4nccs4)CC3)c(Cl)cnc2[nH]1,1,Preclinical,Aurora kinase inhibitor,targeted cancer
parbendazole,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1,1,Preclinical,tubulin polymerization inhibitor,noncancer
metocurine,COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3,0,Launched,acetylcholine receptor antagonist,noncancer
CTS21166,CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O,0,Phase 1,beta-secretase inhibitor,noncancer
zaldaride,CC1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12,1,Phase 3,calmodulin antagonist,noncancer
AZD2858,CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1,1,Preclinical,glycogen synthase kinase inhibitor,noncancer
aminomethyltransferase,CC1CCN=C(N)S1,0,Preclinical,nitric oxide synthase inhibitor,noncancer
EMD-66684,CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,0,Preclinical,angiotensin receptor antagonist,noncancer
"L-798,106",COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1,1,Preclinical,prostanoid receptor antagonist,noncancer
pralidoxime-chloride,C[n+]1ccccc1C[N+][O-],0,Launched,acetylcholinesterase inhibitor,noncancer
sorbitol,OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,0,Launched,mucolytic agent,noncancer
7-hydroxy-DPAT,CCCN(CCC)C1CCc2ccc(O)cc2C1,0,Preclinical,dopamine receptor agonist,noncancer
fenofibrate,CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1,1,Launched,PPAR receptor agonist,noncancer
alprostadil,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O,0,Launched,prostanoid receptor agonist,noncancer
elesclomol,CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1,1,Phase 3,oxidative stress inducer,targeted cancer
falecalcitriol,C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,0,Launched,vitamin D receptor agonist,noncancer
BIX-02188,CN(C)Cc1cccc(N\C(c2ccccc2)=C2/C(=O)Nc3cc(ccc23)C(N)=O)c1,1,Preclinical,MEK inhibitor,targeted cancer
pirinixic-acid,Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C,0,Preclinical,PPAR receptor agonist,noncancer
gatifloxacin,COc1c(N2CCNC(C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1,0,Withdrawn,bacterial DNA gyrase inhibitor,noncancer
propofol,CC(C)c1cccc(C(C)C)c1O,0,Launched,benzodiazepine receptor agonist,noncancer
ziprasidone,Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12,1,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
CAY10505,Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1,0,Preclinical,PI3K inhibitor,Unknown
MPEP,Cc1cccc(n1)C#Cc1ccccc1,0,Preclinical,glutamate receptor antagonist,noncancer
oxiconazole,Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
posaconazole,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O,1,Launched,sterol demethylase inhibitor,noncancer
zolantidine,C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1,1,Preclinical,histamine receptor antagonist,noncancer
fadrozole,N#Cc1ccc(cc1)C1CCCc2cncn12,0,Launched,aromatase inhibitor,targeted cancer
sulbentine,S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1,0,Preclinical,other antifungal,noncancer
oxonic-acid,OC(=O)c1nc(=O)[nH]c(=O)[nH]1,1,Preclinical,uricase inhibitor,noncancer
pentylenetetrazol,C1CCc2nnnn2CC1,0,Withdrawn,GABA receptor antagonist,noncancer
triptorelin,CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,0,Launched,gonadotropin releasing factor hormone receptor agonist,targeted cancer
midodrine,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,1,Launched,adrenergic receptor agonist,noncancer
midostaurin,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,1,Launched,"FLT3 inhibitor, KIT inhibitor, PKC inhibitor",targeted cancer
meprylcaine,CCCNC(C)(C)COC(=O)c1ccccc1,0,Preclinical,local anesthetic,noncancer
crystal-violet,CN(C)c1ccc(cc1)C(c1ccc(cc1)N(C)C)=C1C=CC(C=C1)=[N+](C)C,1,Launched,other antibiotic,Unknown
ilomastat,CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO,1,Phase 3,matrix metalloprotease inhibitor,noncancer
retigabine,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N,0,Launched,potassium channel activator,noncancer
pozanicline,Cc1ncccc1OC[C@@H]1CCCN1,0,Phase 2,acetylcholine receptor antagonist,noncancer
DPI-201106,OC(COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1,1,Phase 2,sodium channel activator,noncancer
8-hydroxy-DPAT,CCCN(CCC)C1CCc2cccc(O)c2C1,0,Preclinical,serotonin receptor agonist,noncancer
BYK-204165,Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12,0,Preclinical,PARP inhibitor,noncancer
GP1a,Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1,0,Preclinical,cannabinoid receptor agonist,noncancer
DU-728,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O,1,Phase 1,structural glycoprotein antagonist,targeted cancer
ORE1001,CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O,0,Phase 1/Phase 2,angiotensin converting enzyme inhibitor,noncancer
theophylline,Cn1c2nc[nH]c2c(=O)n(C)c1=O,1,Launched,adenosine receptor antagonist,noncancer
fruquintinib,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,0,Phase 3,VEGFR inhibitor,targeted cancer
ibrutinib,Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C,1,Launched,Bruton's tyrosine kinase (BTK) inhibitor,targeted cancer
dexamethasone-acetate,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O,1,Launched,glucocorticoid receptor agonist,noncancer
P276-00,CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,1,Phase 2,CDK inhibitor,Unknown
TG-100801,Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl,0,Phase 2,"src inhibitor, VEGFR inhibitor",targeted cancer
SU014813,Cc1[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,1,Phase 2,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
afobazole,CCOc1ccc2[nH]c(SCCN3CCOCC3)nc2c1,1,Launched,anxiolytic,noncancer
PAC-1,Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1,1,Phase 1,caspase activator,targeted cancer
astragaloside-a,CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C,0,Preclinical,antiinflammatory agent,noncancer
"2,3-DCPE",OCCNCCCOc1cccc(Cl)c1Cl,1,Preclinical,Bcl-XL downregulator,targeted cancer
fomocaine,C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1,0,Launched,voltage-gated sodium channel modulator,noncancer
PD-407824,Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1,1,Preclinical,PKC inhibitor,targeted cancer
PSI-7976,CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,Preclinical,HCV inhibitor,noncancer
balicatib,CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N,0,Phase 2,cathepsin inhibitor,noncancer
flumazenil,CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21,0,Launched,benzodiazepine receptor antagonist,noncancer
ipratropium,CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
mefexamide,CCN(CC)CCNC(=O)COc1ccc(OC)cc1,1,Preclinical,psychoactive drug,noncancer
parecoxib,CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
AZD6765,NC(Cc1ccccn1)c1ccccc1,0,Phase 2,glutamate receptor antagonist,noncancer
tolmetin,Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C,0,Launched,cyclooxygenase inhibitor,noncancer
cyclopentolate,CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1,0,Launched,acetylcholine receptor antagonist,noncancer
PG-9,CC(C(=O)OC1CC2CCC(C1)N2C)c1ccc(Br)cc1,0,Preclinical,acetylcholine receptor agonist,noncancer
fingolimod,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,0,Launched,"immunosuppressant, sphingosine phosphate receptor agonist",noncancer
barasertib-HQPA,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1,1,Phase 2/Phase 3,Aurora kinase inhibitor,targeted cancer
SU3327,Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1,1,Preclinical,JNK inhibitor,noncancer
2-deoxyglucose,OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O,0,Phase 2,glycolysis inhibitor,targeted cancer
clobetasone-butyrate,CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl,0,Launched,corticosteroid agonist,noncancer
chlorphenamine,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer
LOXO-101,O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F,0,Phase 2,tropomyosin receptor kinase inhibitor,targeted cancer
ARC-239,COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1,0,Preclinical,adrenergic receptor antagonist,noncancer
quipazine,C1CN(CCN1)c1ccc2ccccc2n1,0,Preclinical,serotonin receptor agonist,noncancer
nolatrexed,Cc1ccc2nc(N)nc(O)c2c1Sc1ccncc1,0,Phase 3,thymidylate synthase inhibitor,targeted cancer
sofalcone,CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1,0,Launched,mucus protecting agent,noncancer
o-3M3FBS,Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F,0,Preclinical,phospholipase activator,noncancer
perflubron,FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br,0,Launched,contrast agent,noncancer
alexidine,CCCCC(CC)C\N=C(/N)N\C(N)=N\CCCCCC\N=C(/N)N\C(N)=N\CC(CC)CCCC,1,Preclinical,phosphatidylglycerophosphatase inhibitor,targeted cancer
biotin,OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,0,Launched,vitamin B,noncancer
